[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
Elin Pauwels(KU Leuven), Christophe M. Deroose(KU Leuven), Sander Jentjens(KU Leuven), Marie Bex(KU Leuven), Michel Koole(KU Leuven), Kim Serdons(KU Leuven), Kristof Baete(KU Leuven), Guy Bormans(KU Leuven), Sofie Celen(KU Leuven), Koen Van Laere(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Marleen Renard, Oliver Bechter(Universitair Ziekenhuis Leuven)
European Journal of Nuclear Medicine and Molecular Imaging
November 26, 2022
Cited by 23
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573